ADAG

Phase 2 Clinical Trial Initiation: Adagene Inc. has commenced a Phase 2 clinical trial for muzastotug in combination with KEYTRUDA for patients with microsatellite stable colorectal cancer, with the first patient dosed in October 2025 and trial completion expected by early 2027.

Trial Design and Objectives: The trial will randomize patients to receive either 10 mg/kg or 20 mg/kg of muzastotug, focusing on overall response rate (ORR) as the primary endpoint, while secondary endpoints include duration of response, progression-free survival, and overall survival.

Previous Trial Results: In a prior Phase 1b/2 trial, muzastotug demonstrated promising results, with a 29% ORR in the 20 mg/kg cohort and favorable median overall survival rates compared to existing treatments.

Company Overview: Adagene is a biotechnology company specializing in antibody-based cancer immunotherapies, utilizing advanced technologies like SAFEbody to enhance safety and efficacy in targeting tumors while minimizing off-target effects.

Analyst Coverage Initiation: LUCID CAPITAL MARKETS has initiated coverage of Adagene Inc. (NasdaqGM:ADAG) with a Buy recommendation, projecting a 377.44% upside based on an average one-year price target of $9.84/share.

Fund Sentiment and Ownership: There has been a 15% increase in the number of funds reporting positions in Adagene, although total shares owned by institutions decreased by 20.15% over the last three months.

Adagene's Presentation at CSCO Meeting: Adagene Inc. will present findings on its drug ADG126 at the CSCO Meeting in Jinan, China, highlighting its combination with pembrolizumab for treating advanced microsatellite stable colorectal cancer (MSS CRC).

Promising Results of ADG126: The drug has shown an objective response rate of approximately 30% and a median overall survival of 19.4 months in patients with refractory MSS CRC, while maintaining a low incidence of severe treatment-related adverse events.